News Headlines

  1. Abzena Recognized As A Market-Leading Antibody-Drug Conjugate CDMO In Frost & Sullivan Radar Report 3/18/2026

    Abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates, today announced it has been named a leader in the Frost Radar™ Report for Antibody Drug Conjugate Contract Development and Manufacturing Organizations.

  2. CEO Insights And Trends: The Future Of The Sterile Filling CDMO Industry 3/17/2026

    Denis Johnson, CEO, explores developments in the CDMO sector and reveals how GRAM is gearing up for its latest phase of growth in sterile filling.

  3. BD Announces $110 Million To Support U.S. Pharmaceutical Supply Chain For Biologic Drugs 3/16/2026

    BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a $110 million investment to expand its production of prefillable syringes, helping accelerate biologic and GLP-1 drug delivery and supporting pharmaceutical reshoring in the U.S.

  4. BD And Ypsomed Expand Partnership To Address Rapidly Growing Biologics Market 3/16/2026

    BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Ypsomed, a leading developer of injection systems, are strengthening their collaboration with the development of a 5.5 mL version of the BD Neopak™ XtraFlow™ Glass Prefillable Syringe.

  5. 3PBIOVIAN And INC Partner To Expand Access To Oncology Treatments In Colombia Through Biosimilar Development 3/13/2026
  6. Earendil Labs And WuXi Biologics Enter Strategic Collaboration To Accelerate Development And Manufacturing Of Bispecific/Multispecific Antibodies And ADCs 3/12/2026

    Earendil Labs, a global leader in AI-driven research and development of next-generation biologics therapeutics, and WuXi Biologics (2269.HK), a global leading Contract Research, Development and Manufacturing Organization (CRDMO), today jointly announced the signing of a strategic collaboration agreement on the development and manufacturing of multiple novel bispecific and multispecific antibodies and ADC candidates in Earendil Labs' pipeline targeting autoimmune disease, cancer, and other diseases.

  7. Trenchant BioSystems And Invetech Group Complete Strategic Alliance Formation To Develop Fully Automated CGT Manufacturing Solution 3/12/2026

    Trenchant BioSystems Inc., the CGT manufacturing platform developer for gene-modified cells, and Invetech, a global leader in solving complex manufacturing and product development challenges in the advanced therapies and diagnostics markets, announce that they have entered into a strategic alliance, The alliance will collaborate on the continued development of Trenchant’s fully automated AutoCell Platform, intended for future commercialization.

  8. Fujifilm Invests In VALANX Biotech To Strengthen ADC CDMO Capabilities 3/12/2026

    FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announces its investment in VALANX Biotech (Vienna, Austria; hereinafter “VALANX”), an Austrian biotechnology company with advanced manufacturing technologies for antibody-drug conjugates (ADCs), one of the key next-generation biopharmaceutical modalities.

  9. Merck Signs MoU With Cyto-Facto To Advance Cell And Gene Therapy Development And Manufacturing In APAC 3/11/2026

    Merck, a leading science and technology company, has signed a non-binding Memorandum of Understanding (MoU) with Cyto-Facto Inc., a specialist CDMO (Contract Development and Manufacturing Organization) focused on cell and gene therapies.

  10. Chiesi And Bespak Partner To Advance Carbon Minimal Inhaler Production With UK Manufacturing Site 3/11/2026

    Chiesi Group ("Chiesi"), the international research focused biopharmaceutical company and a certified B Corp, and Bespak, the specialist inhalation CDMO focused on pulmonary and nasal drug delivery, today announced an expansion of their long-standing partnership, increasing pressurized metered dose inhaler (pMDI) manufacturing capacity at Bespak’s Holmes Chapel site to support the next phase of Chiesi’s Carbon Minimal Inhaler (CMI) program.